All In Biotech

Drug Trial Radar · NCT04304053

Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention

Treatment of Non-severe Confirmed Cases of COVID-19 and Chemoprophylaxis of Their Contacts as Prevention Strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study)

Last checked: Nov 20, 2026Latest source record: Jun 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,300 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,300

Actual

Start

Mar 18, 2020

Primary completion

Jun 15, 2020

Study completion Jun 15, 2020

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Germans Trias i Pujol Hospital; Department of Health, Generalitat de Catalunya; Laboratorios Gebro Pharma SA; Laboratorios Rubió; Institut Catala de Salut
First posted
Mar 11, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a research project to evaluate the efficacy of hydroxychloroquine for post-exposure prophylaxis and early treatment of Covid-19. The intervention entails administering prophylactic hydroxychloroquine to all contacts (Study 1) and treating non severe confirmed cases with hydroxychloroquine (Study 2).

Conditions

  • COVID-19

Interventions

  • Treatment and prophylaxisDrug

    Cases will be offered a therapeutic regimen hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7 Contacts will be offered a prophylactic regimen of hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7.

  • Standard Public Health measuresOther

    Isolation of patient and contact tracing as per national guidelines.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Study 1- Clinical and virological outcome in exposed contactsTime frame: Up to 14 days after start of treatment
  2. Study 1- Transmission of SARS-CoV-2 in exposed contactsTime frame: Up to 14 days after start of treatment
  3. Study 2- Virological outcome in index casesTime frame: Up to 7 days after start of treatment
  4. Study 2- Clinical outcome in index casesTime frame: Up to 28 days after start of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Departament de Salut

    Barcelona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.